SantPChawlaMD

Oncology • Santa Monica, CA

Sarcoma

Physician

Join to view full profile

Dr. Chawla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chawla's full profile

Already have an account?

Office
2811 Wilshire Blvd., Suite 414
Santa Monica, CA 90403
Phone+1 310-552-9999

Fax+1 310-552-9999
Is this information wrong?

Summary

Sant P. Chawla, M.D. is one of the world’s authorities in medical treatment and clinical research for bone and soft-tissue sarcomas and sarcoma therapy. Dr. Chawla heads the Sarcoma Oncology Center in Santa Monica, CA where he leads clinical cancer research efforts and conducts groundbreaking clinical research in pancreatic carcinoma, gynecologic tumors, breast cancer, glioblastoma, malignant peripheral nerve sheath tumors, lung cancer and gastrointestinal tumors.

Dr. Chawla serves on the clinical faculty of numerous prestigious cancer centers, including UCLA, USC, John Wayne Cancer Institute at St. John’s Hospital; he has been an adjunct associate professor at Stanford University and is an adjunct associate professor at the University of Texas, M.D. Anderson Cancer Center; and he is a medical oncologist at Cedars Sinai Comprehensive Cancer Center. Over his 30 years of medical and clinical research experience, Dr. Chawla’s research has been a foundation for further breakthroughs in cancer treatment.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
All India Institute of Medical SciencesClass of 1977

Certifications & Licensure

CA State Medical License 1988 - 2026
TX State Medical License 1984 - 2025
IA State Medical License 1986 - 1990
MD State Medical License 1982 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study Using Rexin-G for Breast Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study Using Rexin-G for Sarcoma Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Phase II Study of Intravenous Rexin-G in Osteosarcoma Start of enrollment: 2007 Dec 01
Completed
Phase 2
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies Start of enrollment: 2007 Dec 01
Completed
Phase 1
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma Start of enrollment: 2010 Feb 01
Terminated
Phase 2
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 May 01
Terminated
Phase 2, Phase 3
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
Active, not recruiting
Phase 2
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Start of enrollment: 2010 Dec 01
Completed
Phase 2
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors Start of enrollment: 2011 Apr 01
Completed
Phase 1
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma Start of enrollment: 2011 Dec 01
Unknown status
Phase 2
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Start of enrollment: 2013 Sep 24
Completed
Phase 1, Phase 2
LGX818 for Patients With BRAFV600 Mutated Tumors Start of enrollment: 2014 Jan 14
Terminated
Phase 2
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Start of enrollment: 2014 Mar 01
Completed
Phase 2
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors Start of enrollment: 2014 Aug 01
Completed
Phase 1
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma Start of enrollment: 2014 Sep 02
Completed
Phase 1, Phase 2
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Start of enrollment: 2016 Feb 10
Completed
Phase 2
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes Start of enrollment: 2016 Apr 27
Completed
Phase 1
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Start of enrollment: 2017 May 04
Active, not recruiting
Phase 1
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer Start of enrollment: 2018 May 09
Completed
Phase 2
SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma Start of enrollment: 2020 Jan 03
Active, not recruiting
Phase 2
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma Start of enrollment: 2019 May 15
Recruiting
Phase 2
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Start of enrollment: 2019 Jul 15
Completed
Phase 1
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 Start of enrollment: 2022 Dec 12
Withdrawn
Phase 1, Phase 2
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma Start of enrollment: 2020 Aug 14
Recruiting
Phase 2
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma Start of enrollment: 2021 Sep 09
Recruiting
Phase 2
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Start of enrollment: 2020 Sep 30
Recruiting
Phase 2
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Start of enrollment: 2023 Sep 01
Not yet recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healt...
Richard T Kenney, John K Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P Chawla, Thomas M Polasek, Jason Lickliter, Philip J Ryan> ;Frontiers in Immunology. 2024 Jan 1
1 citations
The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-r...
Yusuke Aoki, Yutaro Kubota, Qinghong Han, Noriyuki Masaki, Koya Obara, Michael Bouvet, Sant P Chawla, Yasunori Tome, Kotaro Nishida, Robert M Hoffman> ;Cancer Genomics & Proteomics. 2023 Dec 1
From Mendel to Gene Therapy.
Samantha L Jeffrey, Don A Brigham, Sant P Chawla, Noah Federman, Frederick L Hall, Erlinda M Gordon> ;Anticancer Research. 2023 Oct 1
1 citations
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Vivek Subbiah, Sant P Chawla, Anthony P Conley, Breelyn A Wilky, Anthony Tolcher, Nehal J Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim...> ;Clinical Cancer Research. 2023 Aug 15
2 citations
Early-stage+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, aInhibitor.
Sant P Chawla, Olga Olevsky, Geeta Iyengar, Don A Brigham, Sonu Thomas, Kushal Suryamohan, Leland Foshag, Frederick L Hall, Erlinda M Gordon, Nadezhda Omelchenko> ;Anticancer Research. 2023 Jun 1
1 citations
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma.
Natalie K Heater, Scott Okuno, Steven Robinson, Steven Attia, Mahesh Seetharam, Brittany L Siontis, Janet Yoon, Sant Chawla, Mohammed M Milhem, Varun Monga, Keith Skub...> ;Journal of Clinical Medicine. 2023 Mar 29
7 citations
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.
Erlinda Maria Gordon, Sant P Chawla, Walter Andree Tellez, Elan Younesi, Sonu Thomas, Victoria S Chua-Alcala, Hripsime Chomoyan, Chrysler Valencia, Don Arlen Brigham, ...> ;Cancers. 2023 Jan 31
Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
Chenyu Lin, Ahmed Galal, David Rizzieri, Sant Chawla, Seung T Lee, Angela Georgy, Kristina Dabovic, Thomas Strack, Matthew McKinney> ;Cancer Investigation. 2023 Jan 31
2 citations
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).
Sant P Chawla, Walter Andree Tellez, Hripsime Chomoyan, Chrysler Valencia, Amir Ahari, Don A Brigham, Victoria Chua-Alcala, Doris Quon, Ania Moradkhani, Erlinda M Gord...> ;Frontiers in Oncology. 2023 Jan 1
1 citations
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
Xiaofei Zhou, Debra L Richardson, Afshin Dowlati, Sanjay Goel, Solmaz Sahebjam, James Strauss, Sant Chawla, Ding Wang, Diane R Mould, Vivek Samnotra, Douglas V Faller,...> ;Clinical Pharmacology in Drug Development. 2023 Mar 1
4 citations
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.
James Nguyen, Naoko Takebe, Shivaani Kummar, Albiruni Razak, Sant P Chawla, Suzanne George, Shreyaskumar R Patel, Mary Louise Keohan, Sujana Movva, Geraldine O'Sulliva...> ;Clinical Cancer Research. 2023 Apr 3
8 citations
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Federico Longo-Muñoz, Daniel Castellano, Jerome Alexandre, Sant P Chawla, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Ali Zeaiter, Victor Moren...> ;European Journal of Cancer. 2022 Sep 1
3 citations
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline-inactivating mutations.
Jordi Rodón, Pauline Funchain, Theodore W Laetsch, Hendrik-Tobias Arkenau, Alice Hervieu, Christian F Singer, Yonina R Murciano-Goroff, Sant P Chawla, Kristin Anthony,...> ;Future Oncology. 2022 Sep 1
7 citations
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T Loggers, Michael B Livingston, Jennifer Wright, Sant P Chaw...> ;Cancer Medicine. 2023 Jan 1
5 citations
Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma.
Richard F Riedel, Victoria Chua, Ania Moradkhani, Natalie Krkyan, Amir Ahari, Atsushi Osada, Sant P Chawla> ;The Oncologist. 2022 Oct 1
14 citations
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz ...> ;Journal of Clinical Oncology. 2022 Aug 1
8 citations
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I Shapiro, Ant...> ;Clinical Cancer Research. 2022 Jul 1
3 citations
Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.
Mario E Lacouture, Shari B Goldfarb, Alina Markova, Sant P Chawla, Karan Dewnani, Marc Iacobucci, Julie E Lang> ;Breast Cancer Research and Treatment. 2022 Jul 1
49 citations
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
Mrinal M Gounder, Narasimhan P Agaram, Sally E Trabucco, Victoria Robinson, Richard A Ferraro, Sherri Z Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim Abida...> ;Nature Communications. 2022 Jun 15
1 citations
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.
Demetri, G., De Braud, F., Drilon, A., Siena, S., Patel, M., Cho, B., Liu, S., Ahn, M., Chiu, C., Lin, J., Goto, K., Lee, J., Bazhenova, L., John, T., Fakih, M., Chawl...> ;Clinical Cancer Research. 2022 May 13
3 citations
Qualitative study to characterize patient experience and relevance of patient-reported outcome measures for patients with metastatic synovial sarcoma.
Laurie Eliason, Laura Grant, Anya Francis, Anna Cardellino, Ken Culver, Sant P Chawla, Rob Arbuckle, Shibani Pokras> ;Journal of Patient-Reported Outcomes. 2022 May 4
10 citations
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
Robin L Jones, Vinod Ravi, Andrew S Brohl, Sant Chawla, Kristen N Ganjoo, Antoine Italiano, Steven Attia, Melissa A Burgess, Katherine Thornton, Lee D Cranmer, Maggie ...> ;JAMA Oncology. 2022 May 1
52 citations
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
Demetri, G., De Braud, F., Drilon, A., Siena, S., Patel, M., Cho, B., Liu, S., Ahn, M., Chiu, C., Lin, J., Goto, K., Lee, J., Bazhenova, L., John, T., Fakih, M., Chawl...> ;Clinical Cancer Research. 2022 Apr 1
11 citations
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia LoRusso, Joseph Paul Eder, Martin Gutierrez, Kumar Sankh...> ;Clinical Cancer Research. 2021 Sep 13
14 citations
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.
Mark Agulnik, Brian C Schulte, Steven I. Robinson, Angela C. Hirbe, Kevin Kozak, Sant P. Chawla, Steven Attia, Alfred Rademaker, Hui Zhang, Susan Abbinanti, Rasima Ceh...> ;European Journal of Cancer. 2021 Jul 17
Join now to see all

Lectures

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1 soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient surv...
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal TrialDecember 10th, 2020
TYME Announces Outcome of Interim Futility Review for HopES Sarcoma Phase II StudyAugust 11th, 2020
Immix Doses First Patient in USA in Its Phase 1b/2a Trial in Patients with Advanced Solid TumorsFebruary 4th, 2020
Join now to see all